The World Health Organisation (WHO) is making significant strides in its efforts to contain Mpox through the introduction of two in vitro diagnostic tests as part of its Emergency Use Listing (EUL) procedure. This initiative comes at a critical time as health authorities aim to effectively diagnose and manage Mpox infections within affected communities.
In a recent statement, WHO announced the inclusion of the Xpert Mpox test, a real-time PCR test manufactured by Cepheid, and the cobas MPXV assay, developed by Roche Molecular Systems Inc., in its EUL. These diagnostic tools are designed to provide healthcare professionals with the means to accurately identify Mpox infections, which is essential for timely treatment and containment.
The Polymerase Chain Reaction (PCR) testing method, recognized as the gold standard for diagnosing Mpox, detects the viral DNA responsible for the infection. The Xpert Mpox test stands out for its user-friendly operation, delivering results in under 40 minutes, making it a valuable asset in clinical settings where rapid diagnosis is crucial. Similarly, the cobas MPXV assay, designed for use on cobas 6800/8800 Systems, can detect both Mpox clades and provides results in less than two hours, further enhancing diagnostic capabilities.
WHO’s commitment to facilitating the availability of these tests extends beyond their listing. The organization is collaborating with manufacturers of the EUL-listed products and national regulatory authorities in affected countries, including Lesotho, to streamline the processes for domestic registration or emergency listing. By fast-tracking approvals and applying reliance principles, WHO aims to enhance access to quality-assured Mpox tests, ensuring that healthcare providers are equipped with the necessary tools to combat the outbreak effectively.
The proactive measures taken by the WHO in response to Mpox underscore the importance of timely diagnostics in managing public health emergencies. As Lesotho continues to grapple with the challenges posed by infectious diseases, the introduction of these advanced diagnostic tests is a promising development in the fight against Mpox, ultimately aiming to safeguard the health of the population.
As the situation evolves, the collaboration between international health organizations, local authorities, and healthcare professionals will be vital in ensuring a comprehensive response to Mpox and other public health challenges that may arise in the future.
